[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer * An analysis of a phase 3 trial found that Novo's (NVO [https://seekingalpha.com/symbol/NVO]) experimental CagriSema (cagrilintide and semaglutide) led to an average 25% weight loss in overweight or obese women at week 68. * Just over 2300 women were included in the analysis. * A second analysis [https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=918569] of ~1900 women examined results based on menopausal status.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.